Deep immune profiling uncovers novel associations with clinical phenotypes of Multisystem Inflammatory Syndrome in Children (MIS-C)

Multisystem Inflammatory Syndrome in Children (MIS-C) is a systemic inflammatory condition that follows SARS-CoV2 infection or exposure in children. Clinical presentations are highly variable and include fever, gastrointestinal (GI) disease, shock, and Kawasaki Disease-like illness (MIS-C/KD). Compared to patients with acute COVID, patients with MIS-C have a distinct immune signature and expansion of TRVB11 expressing T cells. However, the relationship between immunological and clinical phenotypes of MIS-C is unknown. Here, we measured serum biomarkers, TCR repertoire, and SARS-CoV2-specific T cell responses in a cohort of 76 MIS-C patients. Serum biomarkers associated with macrophage and Th1 activation were elevated in patients with shock, consistent with previous reports. Significantly increased SARS-CoV-2-induced IFN-g; IL-2, and TNF-a; production were seen in CD4+ T cells from patients with neurologic involvement and respiratory failure. Diarrhea was associated with a significant reduction in shock-associated serum biomarkers, suggesting a protective effect. TRVB11 usage was highly associated with MIS-C/KD and coronary aneurysms, suggesting a potential biomarker for these manifestations in MIS-C patients. By identifying novel immunologic associations with the different clinical phenotypes of MIS-C, this study provides insights into the clinical heterogeneity of MIS-C. These unique immunophenotypic associations could provide biomarkers to identify patients at risk for severe complications of MIS-C, including shock and MIS-C/KD.

[1]  R. Yeung,et al.  Kawasaki disease and MIS-C share a host immune response , 2022, Nature Reviews Rheumatology.

[2]  L. S. Schmidt,et al.  Incidence and clinical phenotype of multisystem inflammatory syndrome in children after infection with the SARS-CoV-2 delta variant by vaccination status: a Danish nationwide prospective cohort study , 2022, The Lancet Child & Adolescent Health.

[3]  M. Askenazi,et al.  Immunopathological signatures in multisystem inflammatory syndrome in children and pediatric COVID-19 , 2022, Nature Medicine.

[4]  Y. Saeys,et al.  TIM3+ TRBV11-2 T cells and IFNγ signature in patrolling monocytes and CD16+ NK cells delineate MIS-C , 2021, The Journal of experimental medicine.

[5]  E. Wherry,et al.  Proteomic profiling of MIS-C patients indicates heterogeneity relating to interferon gamma dysregulation and vascular endothelial dysfunction , 2021, Nature Communications.

[6]  D. Singh-Grewal,et al.  Multisystem inflammatory syndrome in children and Kawasaki disease: a critical comparison , 2021, Nature Reviews Rheumatology.

[7]  M. H. Cheng,et al.  HLA class I-associated expansion of TRBV11-2 T cells in Multisystem Inflammatory Syndrome in Children. , 2021, The Journal of clinical investigation.

[8]  J. Faith,et al.  Limited intestinal inflammation despite diarrhea, fecal viral RNA and SARS-CoV-2-specific IgA in patients with acute COVID-19 , 2020, Scientific Reports.

[9]  P. Palma,et al.  The Immunology of Multisystem Inflammatory Syndrome in Children with COVID-19 , 2020, Cell.